Advagene Biopharma Co. Ltd. (6709.TWO) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Taiwan

Price
23.10 TWD
Market cap
1.60 bn TWD
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
-44.85 %
Return on assets (ROA)
-41.01 %

Advagene Biopharma Co. Ltd. financials

Fiscal year20242025
Operating income-70.82 m TWD-70.92 m TWD
EBIT-69.27 m TWD-68.11 m TWD
Net income-69.42 m TWD-68.29 m TWD
Diluted EPS – continuing operations-1.16 TWD-1.14 TWD

Full history since 2017, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Advagene Biopharma Co. Ltd.

Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. The company engages in the development of nasal spray influenza and COVID-19 vaccine; respiratory allergy treatment vaccine, including rhinitis and athsma; and other vaccines. Advagene Biopharma Co., Ltd. was founded in 2006 and is based in Taipei, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.